Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).

CONCLUSIONS: Cabozantinib demonstrated minimal activity in the second- and third-line treatments of clear cell ovarian, fallopian tube or primary peritoneal carcinoma. PMID: 29739622 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29739622?dopt=Abstract

Source: Gynecologic Oncology - May 5, 2018 Category: Cancer & Oncology Authors: Konstantinopoulos PA, Brady WE, Farley J, Armstrong A, Uyar DS, Gershenson DM Tags: Gynecol Oncol Source Type: research